DE60229959D1 - Kombinationstherapie zur behandlung von krebs - Google Patents

Kombinationstherapie zur behandlung von krebs

Info

Publication number
DE60229959D1
DE60229959D1 DE60229959T DE60229959T DE60229959D1 DE 60229959 D1 DE60229959 D1 DE 60229959D1 DE 60229959 T DE60229959 T DE 60229959T DE 60229959 T DE60229959 T DE 60229959T DE 60229959 D1 DE60229959 D1 DE 60229959D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60229959T
Other languages
English (en)
Inventor
Jaime Masferrer
Parul Doshi
Julie Cherrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Pharmacia LLC
Original Assignee
Sugen LLC
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC, Pharmacia LLC filed Critical Sugen LLC
Application granted granted Critical
Publication of DE60229959D1 publication Critical patent/DE60229959D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60229959T 2001-08-15 2002-08-15 Kombinationstherapie zur behandlung von krebs Expired - Fee Related DE60229959D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31241301P 2001-08-15 2001-08-15
PCT/US2002/025797 WO2003015608A2 (en) 2001-08-15 2002-08-15 Combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
DE60229959D1 true DE60229959D1 (de) 2009-01-02

Family

ID=23211320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229959T Expired - Fee Related DE60229959D1 (de) 2001-08-15 2002-08-15 Kombinationstherapie zur behandlung von krebs

Country Status (36)

Country Link
US (1) US7320996B2 (de)
EP (1) EP1427326B1 (de)
JP (1) JP2005501843A (de)
KR (1) KR100656004B1 (de)
CN (1) CN1541098A (de)
AP (1) AP2004002995A0 (de)
AR (1) AR038957A1 (de)
AT (1) ATE414512T1 (de)
AU (1) AU2002329744B2 (de)
BG (1) BG108622A (de)
BR (1) BR0211978A (de)
CA (1) CA2457745A1 (de)
CO (1) CO5560544A2 (de)
CZ (1) CZ2004356A3 (de)
DE (1) DE60229959D1 (de)
EA (1) EA008137B1 (de)
EC (1) ECSP045021A (de)
GE (1) GEP20063868B (de)
HR (1) HRP20040170A2 (de)
HU (1) HUP0500424A3 (de)
IL (1) IL159887A0 (de)
IS (1) IS7137A (de)
MA (1) MA27060A1 (de)
MX (1) MXPA04001464A (de)
NO (1) NO20040516L (de)
NZ (1) NZ530792A (de)
OA (1) OA12651A (de)
PE (1) PE20030332A1 (de)
PL (1) PL368921A1 (de)
RS (1) RS13204A (de)
SK (1) SK1412004A3 (de)
TN (1) TNSN04015A1 (de)
TW (1) TWI230609B (de)
UA (1) UA77002C2 (de)
WO (1) WO2003015608A2 (de)
ZA (1) ZA200400849B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045307A2 (en) * 2001-11-21 2003-06-05 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
DE10393799T5 (de) * 2002-11-27 2005-10-13 Allergan, Inc., Irvine Kinaseinhibitoren für die Behandlung von Erkrankungen
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
CN1747950A (zh) 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
CA2541265A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
MX2007014087A (es) * 2005-05-12 2008-02-07 Pfizer Combinaciones y procedimientos para usar un compuesto de indolinona.
MX2008000120A (es) * 2005-07-08 2008-09-08 John P Ford Dosis media y empaque de seguridad y cumplimiento para terapia contra el cancer sistemica.
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
GB0813873D0 (en) * 2008-07-30 2008-09-03 Univ Dundee Compounds
EP2181991A1 (de) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Neuartige Sunitinib-Salze
EP2186809A1 (de) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. Neue kristalline Form von Sunitinib-Malat
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
RU2495628C1 (ru) * 2012-04-18 2013-10-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ выбора тактики лечения актинического кератоза
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
CA2904152A1 (en) * 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
CN103923014A (zh) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 环肌酸制备方法
JP6942726B2 (ja) 2016-01-08 2021-09-29 ユークリセス ファーマシューティカルズ，インコーポレイテッド クロメン化合物および第２活性薬剤の併用薬
CN111759883B (zh) * 2020-07-23 2021-09-17 浙江农林大学 山核桃内果皮提取物在制备抗卵巢癌产品中的应用
CN114853736B (zh) * 2022-07-06 2022-10-21 北京鑫开元医药科技有限公司 具有trk抑制活性的化合物、制备方法、组合物及其用途

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE553661A (de) * 1955-12-23
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) * 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3310891A1 (de) * 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
DE3426419A1 (de) * 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
DD290192A5 (de) 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
RU2034842C1 (ru) 1989-07-25 1995-05-10 Алкалоида Ведьесети Дьяр Производные хинолина и способ их получения
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
FR2672596B1 (fr) 1991-02-07 1995-07-13 Roussel Uclaf Nouveaux derives bicycliques azotes, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) * 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5389661A (en) * 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
AU675078B2 (en) 1992-10-28 1997-01-23 Shionogi & Co., Ltd. Benzylidene derivatives
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
DE69406903T2 (de) 1993-01-15 1998-04-09 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
FR2701260B1 (fr) 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
IL109430A0 (en) 1993-04-27 1994-07-31 Wellcome Found Hydroxamic acid derivatives, their preparation and pharmaceutical compositions containing them
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
ATE212985T1 (de) 1993-11-30 2002-02-15 Searle & Co Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren
AU692231B2 (en) 1994-02-10 1998-06-04 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
WO1995030652A1 (en) 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
RU2128175C1 (ru) 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
GB2294879A (en) 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
WO1996013483A1 (en) 1994-10-27 1996-05-09 Merck Frosst Canada Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
CA2206978A1 (en) 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
AU4479096A (en) 1995-01-31 1996-08-21 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
RU2200158C2 (ru) 1995-02-13 2003-03-10 Джи.Ди.Сирл энд Ко. Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
KR19980702372A (ko) 1995-02-21 1998-07-15 구니이 야쓰오 글루타민산 수용체 작용약
JPH11501049A (ja) 1995-04-04 1999-01-26 グラクソ、グループ、リミテッド イミダゾ〔１，２−ａ〕ピリジン誘導体
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
CA2221692A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
EP0828718A1 (de) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo-substituierte hydroxaminsäurederivate als cyclooxygenase-2 und 5-lipoxygenase inhibitoren
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1996041626A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CA2180624C (en) 1995-07-12 2006-12-12 Cheuk Kun Lau Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
HU225506B1 (en) 1995-07-19 2007-01-29 Merck & Co Inc Use of 4-(4-methylsulfonyl-phenyl)-3-phenyl-2-(5h)-furanone for the preparation of medicaments treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
EP0853481A1 (de) 1995-09-27 1998-07-22 Merck Frosst Canada Inc. Zusammensetzungen zur behandlung von entzündungen, die gewisse prostaglandine und ein cyclooxygenase-2 hemmer enthalten
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US6376733B1 (en) 1996-01-25 2002-04-23 Exxonmobil Chemical Patents Inc. Process for production of paraxylene
JP4004541B2 (ja) 1996-02-01 2007-11-07 メルク フロスト カナダ リミテッド Ｃｏｘ―２阻害剤のプロドラッグとしてのアルキル化スチレン
KR19990082260A (ko) 1996-02-01 1999-11-25 하우드 버나드 Cox－２ 억제제의 약물 전구체로서의 디페닐 스틸벤
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
JP2000504723A (ja) 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
AU2250097A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
TR199802049T2 (xx) 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
EP0910571B1 (de) * 1996-05-03 2005-07-20 Abbott Laboratories Antiangiogenische peptiden, dafür kodierende polynukleotide und verfahren zur hemmung der angiogenesis
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
JPH10158234A (ja) 1996-12-02 1998-06-16 Kotobuki Seiyaku Kk ２−フェニルアズレン誘導体及びその製造方法
DK0846689T3 (da) 1996-12-09 2004-04-19 Pfizer Benzimidazolforbindelser
JP4167733B2 (ja) 1996-12-16 2008-10-22 花王株式会社 ＮＦ−κＢ活性化抑制剤
EP0863134A1 (de) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)-2-cyclopenten-1-on zur Verwendung als Inhibitor der Cyclooxygenase-2
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
FR2769311B1 (fr) 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
FR2770131A1 (fr) 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
GB2330833A (en) 1997-10-29 1999-05-05 Merck & Co Inc PREPARATION OF 4-(4-Methylsulfonylphenyl)-2-furanones USEFUL AS COX-2 INHIBITORS
FR2771005B1 (fr) 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
FR2771412B1 (fr) 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
WO2000038519A1 (en) * 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
JP5004392B2 (ja) * 1999-12-22 2012-08-22 スージェン， インク． インドリノン化合物を用いてｃ−ｋｉｔチロシン蛋白質キナーゼ機能を調節する方法
JP2003535038A (ja) * 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
SK287142B6 (sk) * 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
WO2001070210A2 (en) * 2000-03-17 2001-09-27 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound

Also Published As

Publication number Publication date
BR0211978A (pt) 2004-07-20
EA008137B1 (ru) 2007-04-27
ECSP045021A (es) 2004-04-28
HRP20040170A2 (en) 2004-08-31
AP2004002995A0 (en) 2004-03-31
MXPA04001464A (es) 2005-02-17
ATE414512T1 (de) 2008-12-15
NO20040516L (no) 2004-04-13
WO2003015608A2 (en) 2003-02-27
US20030216410A1 (en) 2003-11-20
CA2457745A1 (en) 2003-02-27
CN1541098A (zh) 2004-10-27
HUP0500424A3 (en) 2008-04-28
EA200400235A1 (ru) 2004-10-28
PL368921A1 (en) 2005-04-04
HUP0500424A2 (en) 2007-02-28
IL159887A0 (en) 2004-06-20
EP1427326A2 (de) 2004-06-16
JP2005501843A (ja) 2005-01-20
SK1412004A3 (en) 2004-10-05
OA12651A (en) 2006-06-15
CZ2004356A3 (cs) 2004-12-15
GEP20063868B (en) 2006-07-10
AU2002329744B2 (en) 2007-08-30
AR038957A1 (es) 2005-02-02
EP1427326A4 (de) 2005-06-08
CO5560544A2 (es) 2005-09-30
TNSN04015A1 (en) 2006-06-01
WO2003015608A3 (en) 2003-10-30
UA77002C2 (en) 2006-10-16
ZA200400849B (en) 2005-05-03
US7320996B2 (en) 2008-01-22
KR20040043193A (ko) 2004-05-22
EP1427326B1 (de) 2008-11-19
PE20030332A1 (es) 2003-04-05
MA27060A1 (fr) 2004-12-20
KR100656004B1 (ko) 2007-02-28
TWI230609B (en) 2005-04-11
NZ530792A (en) 2005-09-30
RS13204A (en) 2007-02-05
IS7137A (is) 2004-01-30
BG108622A (bg) 2005-10-31

Similar Documents

Publication Publication Date Title
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20034780L (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
FI20012170A (fi) Menetelmä lauhteiden käsittelemiseksi
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
NO334788B2 (no) Fremgangsmåte for behandling av søvnløshet
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee